Last reviewed 2026-05-18 · How we verify

PEMETREXED DIPOTASSIUM

FDA-approved approved Small molecule Quality 21/100

PEMETREXED DIPOTASSIUM is a Folate Analog Metabolic Inhibitor [EPC] drug. It is currently FDA-approved (first approved 2024) for Initial treatment of non-squamous NSCLC, Maintenance treatment of non-squamous NSCLC, Treatment of recurrent non-squamous NSCLC.

Pemetrexed dipotassium is a marketed drug primarily indicated for the initial treatment of non-squamous NSCLC. Its key strength lies in its established market position and the protection afforded by a key composition patent expiring in 2028. The primary risk is the eventual loss of patent protection, which could lead to increased competition from generics.

At a glance

Generic name	PEMETREXED DIPOTASSIUM
Drug class	Folate Analog Metabolic Inhibitor [EPC]
Modality	Small molecule
Phase	FDA-approved
First approval	2024

Approved indications

Initial treatment of non-squamous NSCLC
Maintenance treatment of non-squamous NSCLC
Treatment of recurrent non-squamous NSCLC
Initial treatment of malignant pleural mesothelioma

Common side effects

Neutropenia
Vomiting
Anemia
Stomatitis/Pharyngitis
Thrombocytopenia
Constipation
Fatigue
Nausea
Anorexia
Febrile Neutropenia
Infection
Pyrexia

Serious adverse events

Renal Failure
Febrile Neutropenia

Drug interactions

Ibuprofen

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PEMETREXED DIPOTASSIUM CI brief — competitive landscape report
PEMETREXED DIPOTASSIUM updates RSS · CI watch RSS

Frequently asked questions about PEMETREXED DIPOTASSIUM

What is PEMETREXED DIPOTASSIUM?

PEMETREXED DIPOTASSIUM is a Folate Analog Metabolic Inhibitor [EPC] drug, indicated for Initial treatment of non-squamous NSCLC, Maintenance treatment of non-squamous NSCLC, Treatment of recurrent non-squamous NSCLC.

What is PEMETREXED DIPOTASSIUM used for?

PEMETREXED DIPOTASSIUM is indicated for Initial treatment of non-squamous NSCLC, Maintenance treatment of non-squamous NSCLC, Treatment of recurrent non-squamous NSCLC, Initial treatment of malignant pleural mesothelioma.

What drug class is PEMETREXED DIPOTASSIUM in?

PEMETREXED DIPOTASSIUM belongs to the Folate Analog Metabolic Inhibitor [EPC] class. See all Folate Analog Metabolic Inhibitor [EPC] drugs at /class/folate-analog-metabolic-inhibitor-epc.

When was PEMETREXED DIPOTASSIUM approved?

PEMETREXED DIPOTASSIUM was first approved on 2024.

What development phase is PEMETREXED DIPOTASSIUM in?

PEMETREXED DIPOTASSIUM is FDA-approved (marketed).

What are the side effects of PEMETREXED DIPOTASSIUM?

Common side effects of PEMETREXED DIPOTASSIUM include Neutropenia, Vomiting, Anemia, Stomatitis/Pharyngitis, Thrombocytopenia, Constipation. Serious adverse events: Renal Failure, Febrile Neutropenia.

Drug class: All Folate Analog Metabolic Inhibitor [EPC] drugs
Indication: Drugs for Initial treatment of non-squamous NSCLC
Indication: Drugs for Maintenance treatment of non-squamous NSCLC
Indication: Drugs for Treatment of recurrent non-squamous NSCLC

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing